Article citationsMore>>

S. E. Kjeldsen, S. Julius, G. Mancia, G. T. McInnes, T. Hua, M. A. Weber, A. Coca, S. Ekman, X. Girerd, K. Jamerson, P. Larochelle, T. M. MacDonald, R. E. Schmieder, M. A. Schork, P. Stolt, R. Viskoper, J. Widimsky and A. Zanchetti; VALUE Trial Investigators, “Effects of Valsartan Compared to Amlodipine on Preventing Type 2 Diabetes in High-Risk Hypertensive Patients: The VALUE Trial,” Journal of Hypertension, Vol. 24, No. 7, 2006, pp. 1405-1412. doi:10.1097/01.hjh.0000234122.55895.5b

has been cited by the following article:

• TITLE: Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan

  AUTHORS: Yoichi Oikawa, Akira Shimada, Mizumi Kyo

  KEYWORDS: Albuminuria; Angiotensin II Receptor Blocker (ARB); Candesartan; Hypertension; Type 2 Diabetes

  JOURNAL NAME: Open Journal of Endocrine and Metabolic Diseases, Vol.3 No.5, September 20, 2013

  ABSTRACT: Introduction: It was recently reported that candesartan, an angiotensin II receptor blocker, had a protective effect against cardiovascular events, comparable to that of calcium channel antagonists. Moreover, a renoprotective effect and anti-diabetic action of candesartan had also been demonstrated. However, whether the renoprotective effect of candesartan, especially in diabetes, was dose-dependent or not remain to be fully elucidated. The present study attempted to clarify the dose effect of renoprotection by candesartan in Japanese type 2 diabetic patients. Subjects and Method: In this case series study, we recruited 26 type 2 diabetic patients with albuminuria whose blood pressure did not reach the target BP level ( were increased to the maximal dose in Japan, 12 mg/day. Clinical parameters were examined before, at 6 and 12 months after the increase in dose. Results: An ameliorating effect of the increased dose of candesartan on albuminuria and hypertension was distinctly observed. No severe adverse effect was observed. Conclusion: It was highly possible that the maximal dose of candesartan provided more effective renoprotection in hypertensive type 2 diabetic patients initially treated with lower doses of candesartan.